Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals director Daniel Soland resigns from board effective Oct. 30, 2025

Neutral Impact 2 of 5 leadership Written later

Acadia Pharmaceuticals said director Daniel B. Soland resigned from its Board and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The filing states the resignation was not due to any dispute or disagreement with the company or the Board about its operations, policies or practices.

Key points

  • Daniel B. Soland notified the Board of his resignation on October 28, 2025.
  • Resignation is effective October 30, 2025, and covers his Board seat and his committee membership and chair role.
  • The filing says the resignation involved no dispute or disagreement with the company or the Board.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECNov 3, 2025, 4:23 PM ET
Accession number0001193125-25-262610

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.